Press Releases
Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug
GenePOC, a subsidiary of Debiopharm Group, reaches an agreement with Meridian Bioscience for the acquisition of their molecular diagnostics business
Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…
ACTEON has entered into exclusive negotiations to acquire the Dental Division of VILLA SISTEMI MEDICALI
Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections